Johnson & Johnson Lifts 2026 Outlook After $25.31 Billion Q2 Beat

3 articles · Updated · CNBC · Jul 15

$25.31 billion in second-quarter sales and $2.90 adjusted EPS both topped Wall Street estimates, prompting Johnson & Johnson to raise its full-year outlook.
J&J now sees 2026 sales at about $101.1 billion at the midpoint, up from $100.8 billion, and adjusted EPS at $11.68 versus $11.55 previously.
Tremfya drove much of the upside, with sales jumping 72.5% to $2 billion as J&J leans on the drug to replace revenue lost after Stelara's patent expiry.
Darzalex added $4.2 billion in quarterly sales, while the medical-technology unit lagged expectations and Abiomed revenue fell 2% after a U.K. study questioned some Impella pump use.
J&J said it expects Abiomed to return to growth as more data emerge next year, underscoring management's view that its broad portfolio can absorb weakness in any single product.